CLAL BIOTECHNOLOGY INDUSTRIES LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.4 ILa | -3.34% |
|
-8.44% | +9.32% |
| Sales 2022 | 370K 100K 37M | Sales 2023 | 104K 28.22K 10.4M | Capitalization | 62.27M 16.9M 6.23B |
|---|---|---|---|---|---|
| Net income 2022 | -61M -16.55M -6.1B | Net income 2023 | -31M -8.41M -3.1B | EV / Sales 2022 | 331 x |
| Net Debt 2022 | 23.85M 6.47M 2.38B | Net Debt 2023 | 22.4M 6.08M 2.24B | EV / Sales 2023 | 814 x |
| P/E ratio 2022 |
-1.6
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.65% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.34% | ||
| 1 week | -8.44% | ||
| Current month | -8.63% | ||
| 1 month | -8.63% | ||
| 3 months | +3.09% | ||
| 6 months | +3.33% | ||
| Current year | +9.32% |
1 week
43.40
48.00
1 month
43.4053.00
Current year
36.6053.00
1 year
36.6063.00
3 years
36.60267.80
5 years
36.60267.80
10 years
36.60943.00
| Managers | Title | Age | Since |
|---|---|---|---|
Assaf Segal
CEO | Chief Executive Officer | 51 | 15-06-30 |
Liat Nissan
DFI | Director of Finance/CFO | 46 | - |
Arnon Aharon
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 03-05-08 | |
Yuval Yanai
BRD | Director/Board Member | 71 | 15-11-17 |
Gad Keren
BRD | Director/Board Member | 73 | 20-02-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 43.4 | -3.34% | 120 202 |
| 24-05-28 | 44.9 | -3.85% | 178,000 |
| 24-05-27 | 46.7 | -1.89% | 122,035 |
| 24-05-26 | 47.6 | +1.49% | 9,437 |
| 24-05-23 | 46.9 | -1.05% | 101,514 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 29, 2024 at 05:22 am EDT
More quotes
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +9.32% | 19.13M | |
| +21.86% | 82.42B | |
| +77.36% | 19.68B | |
| +13.61% | 18.3B | |
| +10.98% | 14.99B | |
| +1.51% | 13.13B | |
| +2.46% | 11.46B | |
| +1.73% | 10.51B | |
| -1.85% | 9.89B | |
| +29.61% | 9.9B |
- Stock Market
- Equities
- CBI Stock
